Venus Remedies Limited (VENUSREM) AI Stock Analysis

• Market Cap: ₹10.94B
• Dividend Yield: N/A
• Average Volume (3M): 2.33K
• Price to Earnings (P/E): 14.3
• Beta (1Y): 1.10
• Revenue Growth: 13.32%
• EPS Growth: 218.38%
• Country: IN
• Employees: 1,187
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 19.14
• Shares Outstanding: 13,366,988
• 10 Day Avg. Volume: 2,529
• 30 Day Avg. Volume: 2,330
• PEG Ratio: 0.16
• Price to Book (P/B): 0.75
• Price to Sales (P/S): 0.65
• P/FCF Ratio: 5.20
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 72 Outperform
• Price Target: ₹908.00 ▲(16.08% Upside)

Venus Remedies Limited's strong financial performance is the primary driver of its score, supported by robust revenue growth and effective cash flow management. The technical analysis suggests strong momentum, though caution is advised due to overbought signals. The valuation is reasonable, but the lack of a dividend yield may deter some investors.

Positive Factors

Cash Generation

Strong free cash flow indicates the company consistently converts earnings into cash after capital expenditures, enabling reinvestment in manufacturing, working capital and R&D. Durable cash generation enhances financial flexibility for capex, deleveraging or opportunistic investments over cycles.

Balance Sheet Strength

A high equity ratio and favorable debt-to-equity signal conservative financing and low leverage, reducing interest burden and distress risk. Improved return on equity shows effective capital use; this balance sheet strength supports sustained investment, resilience to shocks and long-term strategic options.

Improving Profitability & Margins

Sustained gross margins and rising net margins reflect efficient production, pricing power in hospital formulations and better cost control. Stable EBIT/EBITDA margins suggest earnings quality that can fund capacity, product development and absorb input-cost inflation over the medium term.

Negative Factors

Product/Segment Concentration

Concentration in hospital and critical-care anti-infectives concentrates revenue exposure to institutional procurement, formulary choices and clinical guidelines. Structural shifts in hospital treatment protocols, tender dynamics or intensified competition could materially affect volumes and long-term pricing power.

Limited Geographic Disclosure / Diversification

Absence of a market-wise revenue breakdown limits visibility on geographic diversification and exposes the firm to single-market concentration risk. If domestic or a few export markets dominate, regulatory, reimbursement or demand shocks in those geographies could disproportionately impact revenue sustainability.

Regulatory Dependence for Exports

Reliance on product registrations and approvals ties international growth to regulatory timelines and compliance. Delays, evolving standards or inspection outcomes create structural bottlenecks for export expansion and can defer revenue recognition across multiple quarters, limiting predictable scaling.

Venus Remedies Limited Business Overview & Revenue Model

Company Description

Venus Remedies Limited develops and markets pharmaceutical products in India and internationally. The company offers its products in various therapeutic areas, such as analgesic, analgesic and antipyretic, anti-diabetic, antibiotic, anticoagulant, cardiac, disinfectant and antiseptic, gastro therapy, hand sanitizers, hormones, iron supplements, neurology, oncology, pain management, respiratory, skin and wound care, stress reliever, urology, and vitamins/minerals/nutrients, as well as antimicrobial resistance products. It also provides disinfectants; and a portfolio of herbal products. Venus Remedies Limited was incorporated in 1989 and is headquartered in Panchkula, India.

How the Company Makes Money

Venus Remedies generates revenue primarily through the sale of its pharmaceutical products, which include a wide array of generic drugs and proprietary formulations. Key revenue streams include domestic sales within India and international sales through exports to various markets, including Europe, the Middle East, and Africa. The company also earns income from contract manufacturing services, allowing it to leverage its production capabilities for third-party clients. Strategic partnerships with healthcare providers and distributors enhance its market reach and facilitate entry into new geographical markets. Additionally, research and development investments lead to the creation of innovative products, contributing to long-term revenue growth.

Venus Remedies Limited Financial Statement Overview

Summary

Venus Remedies Limited demonstrates a strong financial position with consistent revenue growth, robust profit margins, and effective cash flow management. The company exhibits financial stability with a low reliance on debt and a strong equity base, suggesting a solid financial foundation and potential for sustained growth.

Income Statement

Venus Remedies Limited has demonstrated strong revenue growth over the years, with a significant increase from 2020 to 2025. The company maintains a healthy Gross Profit Margin, indicating efficient production and cost management. The Net Profit Margin has improved significantly compared to earlier losses, reflecting enhanced operational efficiency and profitability. The EBIT and EBITDA margins are solid, showcasing robust earnings performance before interest, taxes, and non-cash expenses.

Balance Sheet

The company displays a strong equity position with a high Equity Ratio, suggesting financial stability and a low reliance on debt. The Debt-to-Equity Ratio is favorable, indicating low financial leverage and reduced risk of financial distress. Return on Equity has shown consistent improvement, reflecting effective use of shareholders' equity in generating profits.

Cash Flow

Venus Remedies Limited exhibits strong cash flow performance, with a significant positive Free Cash Flow trend, indicating good cash generation after capital expenditures. The Operating Cash Flow to Net Income Ratio is robust, highlighting efficient conversion of earnings into cash. There is a significant increase in Free Cash Flow over the years, underscoring the company's strong cash-generating capabilities.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	6.71B	6.48B	5.91B	5.56B	5.99B	5.48B
Gross Profit	2.22B	1.66B	2.18B	2.25B	2.00B	1.07B
EBITDA	1.00B	944.10M	711.80M	703.46M	701.40M	968.49M
Net Income	537.10M	453.20M	284.91M	265.70M	407.24M	617.65M
Balance Sheet
Total Assets	0.00	7.16B	6.27B	6.01B	5.80B	5.56B
Cash, Cash Equivalents and Short-Term Investments	1.56B	1.64B	838.05M	720.77M	432.56M	288.79M
Total Debt	0.00	16.90M	413.25M	422.90M	428.45M	513.18M
Total Liabilities	-5.61B	1.55B	1.39B	1.41B	1.39B	1.56B
Stockholders Equity	5.61B	5.61B	4.88B	4.60B	4.40B	4.00B
Cash Flow
Free Cash Flow	0.00	812.90M	278.40M	288.02M	272.94M	1.25B
Operating Cash Flow	0.00	909.20M	372.85M	366.20M	410.01M	1.33B
Investing Cash Flow	0.00	-807.90M	-72.09M	-508.30M	-166.26M	557.16M
Financing Cash Flow	0.00	-9.50M	-10.83M	-5.70M	-94.77M	-1.62B

Venus Remedies Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 782.25
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:VENUSREM, the sentiment is Positive. The current price of 782.25 is above the 20-day moving average (MA) of 750.40, above the 50-day MA of 756.32, and above the 200-day MA of 522.22, indicating a bullish trend. The MACD of 9.18 indicates Negative momentum. The RSI at 62.74 is Neutral, neither overbought nor oversold. The STOCH value of 82.99 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:VENUSREM.

Venus Remedies Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VENUSREM	72 Outperform	₹10.94B	14.33	―	―	13.32%	218.38%
INDSWFTLAB	66 Neutral	₹9.25B	3.11	―	―	-37.70%	-19.79%
ZIMLAB	63 Neutral	₹3.48B	52.76	―	―	-5.82%	-59.22%
KILITCH	57 Neutral	₹5.44B	18.55	―	―	32.95%	67.39%
MEDICAMEQ	57 Neutral	₹4.65B	41.80	―	0.26%	-9.16%	49.09%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NECLIFE	46 Neutral	₹3.01B	-0.85	―	―	-30.27%	-3470.06%

Venus Remedies Limited Corporate Events

Venus Remedies Publishes Unaudited Q3 FY2025 Financial Results in Newspapers

Venus Remedies Limited has notified the stock exchange that it has published its unaudited financial results for the period ended 31 December 2025 in newspapers, in compliance with disclosure requirements under Regulation 30 of the Listing Obligations and Disclosure Requirements (LODR). The move underscores the company’s adherence to statutory transparency and reporting norms, providing stakeholders with timely access to its quarterly financial performance and reinforcing its governance and compliance standards in the pharmaceutical sector.

Venus Remedies Closes Trading Window Ahead of December 2025 Results

Venus Remedies Limited has announced that, in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, its trading window for dealing in the company’s securities will be closed for all designated persons from January 1, 2026 until 48 hours after the declaration of its audited financial results for the period ending December 31, 2025. The move is a routine compliance step aimed at preventing insider trading around the release of key financial information, reinforcing the company’s adherence to regulatory standards and safeguarding transparency for investors and other market participants.

Venus Remedies Opens Special Window for Share Transfer Requests

Venus Remedies Limited has announced the opening of a special window for the re-lodgement of transfer requests for physical shares. This move is in compliance with a SEBI circular issued in July 2025, and the company has communicated this update through its official social media channels. The initiative reflects Venus Remedies’ commitment to adhering to regulatory requirements and ensuring smooth operations for its shareholders.

Venus Remedies Completes AMR Licensing Milestones with Final Payment

Venus Remedies Limited has successfully completed all commercial milestones under its 2019 agreement with Cipla Ltd, receiving a final payment of Rs. 11 crore for its AMR-focused anti-infective product. This milestone underscores the product’s clinical impact, having treated over one million patients without serious adverse events, and highlights Venus Remedies’ commitment to innovation in addressing antimicrobial resistance. The company plans to continue prioritizing AMR with a pipeline of promising antibacterial candidates and ongoing initiatives in surveillance and stewardship.